Pharmatest Services

Pharmatest Services is a specialized preclinical CRO with a strong niche in oncology and skeletal diseases, particularly bone metastases and radiopharmaceutical testing. Leveraging over 25 years of collective experience, the company provides validated, high-predictivity models and analytical services to biopharma clients globally, aiming to de-risk and accelerate their nonclinical development. Its business model is entirely service-based, generating revenue from client projects, and it has established a strong reputation evidenced by long-term partnerships with major pharmaceutical companies. The company operates as a private entity from its modern laboratories in Turku, Finland.

Integrated suite of validated preclinical models and analytical techniques specializing in oncology (xenograft, syngeneic, immuno-oncology, bone metastasis models) and skeletal diseases (osteoporosis, osteoarthritis, rare bone disease). Core capabilities include ex vivo bone histomorphometry & imaging, clinical biomarker analysis, and specialized testing infrastructure for targeted radiopharmaceuticals (alpha-emitters).

Pharmatest competes in the global preclinical CRO market against large, diversified players like Charles River Laboratories and Eurofins, as well as other niche oncology or musculoskeletal-focused CROs. Its key competitive advantages are its deep specialization at the intersection of bone biology and oncology, unique expertise in bone metastasis and radiopharmaceutical models, and a strong reputation for scientific quality among blue-chip pharma clients.